StonvexLoading…
StonvexStonvexStonvexCore line items from IMAX's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q3 2026 (Est.) Expected 2026-07-22 | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|---|
Revenue | $102.65M | $81.38M | $410.21M | $285.00M | $178.35M |
Operating Income | Not available | $9.95M | $84.23M | $60.13M | $31.08M |
Net Income | Not available | $4.23M | $34.88M | $34.24M | $13.58M |
EPS (Diluted) | $0.35 | $0.07 | $0.63 | $0.62 | $0.25 |
Total Assets | Not available | $893.15M | $894.03M | $889.57M | $868.58M |
Total Liabilities | Not available | $464.81M | $466.30M | $452.87M | $463.51M |
Cash & Equivalents | Not available | $146.00M | $151.17M | $143.11M | $109.25M |
Free Cash Flow OCF − CapEx | Not available | $1.90M | $118.90M | $90.94M | $26.18M |
Shares Outstanding | Not available | 54.86M | 53.92M | 53.80M | 53.78M |